PLAsma Genomic Testing in Patients With Advanced Non-Small Cell Lung Cancer: The PLAN Study
This is a multi-centre, prospective, translational study investigating the use of plasma genotyping for initial genomic testing in newly diagnosed advanced/locally advanced non-squamous NSCLC. In this study, patients will have a plasma genotyping assay completed following confirmation of suspected diagnosis of non-squamous NSCLC at institutional Rapid Access Lung Cancer Clinics (RALCC), alongside standard tissue-based biopsy and genotyping.
• Radiological suspicion of advanced or locally advanced non-small cell lung cancer
• Age ≥18 years
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Ability of subject to understand and the willingness to sign a written informed consent document.
• Second arm additional criteria
• Planned for systemic treatment with either single agent immunotherapy (IT) or combination chemotherapy/IT
• No prior systemic therapy for advanced NSCLC